Last reviewed · How we verify
DW-330SR2
DW-330SR2 is a small molecule that targets the renin-angiotensin system.
DW-330SR2 is a small molecule that targets the renin-angiotensin system. Used for Hypertension.
At a glance
| Generic name | DW-330SR2 |
|---|---|
| Sponsor | Daewon Pharmaceutical Co., Ltd. |
| Drug class | ACE inhibitor |
| Target | ACE |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
DW-330SR2 works by inhibiting the angiotensin-converting enzyme (ACE), which is involved in the renin-angiotensin system. This leads to a decrease in blood pressure and a reduction in the risk of cardiovascular events.
Approved indications
- Hypertension
Common side effects
- Cough
- Dizziness
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DW-330SR2 CI brief — competitive landscape report
- DW-330SR2 updates RSS · CI watch RSS
- Daewon Pharmaceutical Co., Ltd. portfolio CI